Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04436393 · ClinicalTrials.gov registry record
Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer
A clinical trial, sponsored by Guardant Health.
- Completed
- Registry status
- 109
- Enrollment target
NCT04436393: Completed study, sponsored by Guardant Health.
NCT04436393 is a clinical trial that has completed, run by Guardant Health. The registered enrollment target is 109 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04436393 has completed, sponsored by Guardant Health.
- COMPLETED
- Registry status
- 109 participants
- Enrollment target
Study Summary
The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.
Primary Outcome
The Primary Outcome measure is a composite endpoint of: overall survival, progression events, and subjects lost-to-follow-up Overall Survival is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
Interventions
- DIAGNOSTIC_TEST Guardant360 test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2020-07-02 |
| Est. Completion | 2022-03-17 |
What the finished NCT04436393 record still lists
NCT04436393 is an observational study that tracks outcomes without assigning an intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Guardant360 test is the first listed.
NCT04436393 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04436393 about?
NCT04436393 is a clinical study titled "Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer". The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.
What is the current status of trial NCT04436393?
This trial is currently completed. The enrollment target is 109 participants. The study started on 2020-07-02. Estimated completion is 2022-03-17.
What interventions are being tested in trial NCT04436393?
The interventions under investigation include: Guardant360 test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04436393?
This trial is sponsored by Guardant Health, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI